Price Alert

Spero Therapeutics Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

2.15

0.01 (0.47%)

At close: Sep 05, 2025, 3:59 PM

2.15

0.00%

After-hours: Sep 05, 2025, 05:13 PM EDT

0.47% (1D)

Bid	2
Market Cap	120.99M
Revenue (ttm)	40.5M
Net Income (ttm)	-54.47M
EPS (ttm)	-0.98
PE Ratio (ttm)	-2.19
Forward PE	-53.5
Analyst	Hold

Ask	2.25
Volume	175,191
Avg. Volume (20D)	1,007,540
Open	2.14
Previous Close	2.14
Day's Range	2.13 - 2.17
52-Week Range	0.51 - 3.22
Beta	1.46

About SPRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-17.8%

Spero Therapeutics shares are trading lower follow... Unlock content with Pro Subscription

1 month ago

-1.36%

Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.

News

2 weeks ago · zacks.com

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

3 weeks ago · seekingalpha.com

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Esther P. Rajavelu - CEO, CFO, President & Treasurer Shai Biran - Corporate Par...

2 months ago · seekingalpha.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a licen...

2 months ago · https://www.defenseworld.net

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO)

Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and ...